Evidence map›Paper›PMID 34331997›Full record

ArticleUrology2021

Functional and Oncological Outcomes of Renal Surgery for Hilar Tumors: Informing the Decisions in Risk-Adapted Management.

Ricardo G Alvim, Amy L Tin, Lucas Nogueira, Nathan C Wong, Renato C Fonseca, Daniel D Sjoberg, A Ari Hakimi, Karim A Touijer, Paul Russo, Jonathan A Coleman

Open access · greenAbstract readComparative Study
In one paragraph

Article in Urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Ricardo G AlvimUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Amy L TinDepartment of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Lucas NogueiraUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Surgery Department, Urology Service, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Nathan C WongUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Renato C FonsecaSurgery Department, Urology Service, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Daniel D SjobergDepartment of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
A Ari HakimiUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Karim A TouijerUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Paul RussoUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Jonathan A ColemanUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: lucasnog@globo.com.
Memorial Sloan Kettering Cancer Center · USUniversidade Federal de Minas Gerais · BR

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

objectiveTo describe the safety and efficacy of partial nephrectomy (PN) in comparison to radical nephrectomy (RN) for surgically managed renal hilar tumors. MATERIALS AND

methodsWe retrospectively reviewed institutional records of patients with a small (<5 cm) solitary renal (hilar or non-hilar) mass who underwent PN or RN between 2008 and 2018. Hilar tumors were defined as those at medial position, abutting the renal vessels. Recurrence-free, cancer-specific, and overall survival were estimated using the Kaplan-Meier method.

resultsOf 1,951 eligible patients, 399 had hilar tumors (292 scheduled for PN, 107 RN) and 1,552 had non-hilar tumors (scheduled for PN). We found no significant differences in survival measures between hilar and non-hilar tumors in patients selected for PN. Patients scheduled for PN for hilar tumors had higher rates of ≥grade II postoperative surgical complications compared to patients scheduled to receive PN for non-hilar tumors (13% vs 8.6%; log-rank P = .018) and non-statistically significantly elevated rates of ≥grade II complications compared to patients scheduled for RN for hilar tumors (13% vs 6.5%; difference 6%, 95% CI 0.4%, 13%; log-rank P = .07).

conclusionPN for hilar and non-hilar renal masses (<5cm) experience comparable oncologic outcomes though increased risk of complications for hilar masses. PN for hilar tumors was associated with better renal function and overall survival with non-statistically elevated risk of grade II or higher complications than RN. A renal tumor located at the hilum should not be a contra-indication for performing PN.

Indexed as

AgedClinical Decision-MakingFemaleGlomerulosclerosis, Focal SegmentalHumansKaplan-Meier EstimateKidneyKidney NeoplasmsMaleMiddle AgedNephrectomyPostoperative ComplicationsRetrospective StudiesRisk AssessmentRisk FactorsSurvival Rate

Identifiers

PMID34331997
PMCPMC8671208
OpenAlexW3191740873

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.